XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

XORTX Therapeutics has completed its acquisition of the VB4-P5 program from Vectus Biosystems, a novel therapeutic targeting kidney fibrosis in chronic kidney disease. The deal valued at US$3.0 million includes patent rights and preclinical data. VB4-P5 is positioned to address a significant unmet medical need in both rare and prevalent kidney diseases affecting millions globally.

04/13/2026, 5:00 PM • GlobeNewswire

XORTX Confirms Effective Date of Share Consolidation

XORTX Therapeutics announced that its 1-for-5 share consolidation has received all required approvals from TSX Venture Exchange and Nasdaq Stock Exchange, effective April 6, 2026. The company is a late-stage clinical pharmaceutical firm developing therapies for gout and progressive kidney disease, with three clinically advanced products in development.

04/01/2026, 1:00 PM • GlobeNewswire

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Therapeutics Inc. held its annual and special shareholder meeting on March 24, 2026, with 35% shareholder representation. All proposed matters were approved, including the election of five board members (Anthony Giovinazzo as Chair, Allen Davidoff as CEO, Mika Grasso, Richard Grieve, and George Scorsis), appointment of Davidson & Company LLP as auditors, re-approval of the stock option plan, and approval of a share consolidation.

03/26/2026, 6:00 PM • GlobeNewswire

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

XORTX Therapeutics Inc. announced shareholder approval for a 5-to-1 share consolidation to maintain compliance with NASDAQ's listing requirements, specifically ensuring shares trade above $1.00. The consolidation will reduce outstanding shares from approximately 6.96 million to 1.39 million and is pending TSX Venture Exchange approval. The company must achieve the $1.00 threshold by April 13, 2026.

03/24/2026, 5:00 PM • GlobeNewswire

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

XORTX Therapeutics announced that independent proxy advisory firm ISS has recommended shareholders vote in favor of the company's proposed share consolidation at the March 24, 2026 shareholder meeting. ISS stated the consolidation should have no direct negative impact on shareholder value and could enhance long-term growth prospects by broadening financing alternatives. The proxy voting deadline is March 20, 2026.

03/13/2026, 7:00 AM • GlobeNewswire

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Therapeutics has extended the deadline to complete its acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program (VB4-P5) to March 31, 2026, allowing additional time for intellectual property transfer. The company also announced its Annual and Special Meeting of Shareholders scheduled for March 24, 2026, and granted stock options to new board member Krysta Davies Foss.

02/04/2026, 6:00 PM • GlobeNewswire

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

XORTX Therapeutics announced peer-reviewed research linking genetic factors to xanthine oxidase over-expression in gout and kidney disease, supporting the company's therapeutic approach. The company appointed Krysta Davies Foss to its board, corrected warrant issuance numbers from a recent $1.1M offering, and provided updates on its pending acquisition of Vectus Biosystems' renal anti-fibrotic program, expected to close by January 13, 2026.

12/31/2025, 6:15 PM • GlobeNewswire

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

XORTX Therapeutics has entered into a securities purchase agreement to sell 1,746,631 common shares at $0.63 per share, expecting to raise approximately $1.1 million for working capital and general corporate purposes.

10/21/2025, 8:00 AM • GlobeNewswire

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, with a deadline of April 13, 2026. Failure to comply could result in delisting.

10/20/2025, 8:34 PM • GlobeNewswire

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

XORTX Therapeutics received a Nasdaq notification that its stock price has been below $1.00 for 30 consecutive business days, triggering a compliance review. The company has 180 calendar days to regain compliance and continue trading on the Nasdaq Capital Market.

10/20/2025, 6:45 PM • GlobeNewswire

Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight

The gout therapeutics market is experiencing steady growth with over 20 companies developing innovative treatments, driven by rising disease prevalence and increasing awareness of potential new therapies.

09/16/2025, 1:00 PM • GlobeNewswire

XORTX Completes USD $114,500 Private Placement

XORTX Therapeutics completed a non-brokered private placement of 156,849 units at $0.73 per unit, raising $114,500. The proceeds will be used for gout programs and corporate purposes.

08/08/2025, 7:54 PM • GlobeNewswire

XORTX Completes Non-Brokered Private Placement of Units

XORTX Therapeutics closed a non-brokered private placement of 1,267,123 units at $0.73 per unit, raising $925,000. The proceeds will be used for gout programs, corporate purposes, and working capital.

07/22/2025, 7:59 PM • GlobeNewswire

XORTX Announces USD $925,000 Private Placement

XORTX Therapeutics plans to raise up to $925,000 through a non-brokered private placement of common share units, with proceeds to be used for advancing gout and kidney disease programs and general corporate purposes.

06/26/2025, 7:00 AM • GlobeNewswire